Eli Lilly posts $24.4B Q3 and raises 2026 guide to $91B-$92B; the midpoint implies Q4 revenue of ~$24.3B, flat with Q3
Eli Lilly (LLY) reported $24.4B of Q3 revenue on Thursday, up 39% from a year ago. It also lifted its 2026 guide to $91B to $92B.
Mounjaro plus Zepbound was ~66% of sales. Take out the $67.2B booked so far and the midpoint implies ~$24.3B for Q4, flat with Q3. Smells like sandbagging. Not financial advice.
https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full
Sources: @m_goes_distance: Eli Lilly's pipeline is out of control, Q3 just dropped, retatrutide ~28% body weight lost at 80 weeks · @elonmusk: Eli Lilly has some banger drugs coming out!
Not financial advice. For informational and educational purposes only.

